Ghomian Nayereh, Khosravi Ashraf, Mousavifar Nezhat
Ovulation Dysfunction Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Int J Fertil Steril. 2015 Apr-Jun;9(1):17-26. doi: 10.22074/ijfs.2015.4204. Epub 2015 Apr 21.
There are still many questions about the ideal protocol for letrozole (LTZ) as the commonest aromatase inhibitor (AI) used in ovulation induction. The aim of this study is to compare the ultrasonographic and hormonal characteristics of two different initiation times of LTZ in clomiphene citrate (CC) failure patients and to study androgen dynamics during the cycle.
This randomized clinical trial was done from March to November 2010 at the Mashhad IVF Center, a university based IVF center. Seventy infertile polycystic ovarian syndrome (PCOS) patients who were refractory to at least 3 CC treatment cycles were randomly divided into two groups. Group A (n=35) receiving 5 mg LTZ on cycle days 3-7 (CD3), and group B (n=35) receiving the same amount on cycle days 5-9 (CD5). Hormonal profile and ultrasonographic scanning were done on cycle day 3 and three days after completion of LTZ treatment (cycle day 10 or 12). Afterward, 5,000-10,000 IU human chorionic gonadotropin (hCG) was injected if at least one follicle ≥18 mm was seen in ultrasonographic scanning. Intrauterine insemination (IUI) has been done 36-40 hours later. The cycle characteristics, the ovulation and pregnancy rate were compared between two groups. The statistical analysis was done using Fisher's exact test, t test, logistic regression, and Mann-Whitney U test.
There were no significant differences between two groups considering patient characteristics. The ovulation rate (48.6 vs. 32.4% in group A and B, respectively), the endometrial thickness, the number of mature follicles, and length of follicular phase were not significantly different between the two groups.
LTZ is an effective treatment in CC failure PCOS patients. There are no significant differences regarding ovulation and pregnancy rates between two different protocols of LTZ starting on days 3 and 5 of menstrual cycle (
IRCT201307096467N3).
对于来曲唑(LTZ)作为排卵诱导中最常用的芳香化酶抑制剂(AI)的理想方案仍存在许多问题。本研究的目的是比较枸橼酸氯米芬(CC)治疗失败患者中LTZ两种不同起始时间的超声和激素特征,并研究周期中的雄激素动态变化。
本随机临床试验于2010年3月至11月在马什哈德体外受精中心进行,该中心是一家基于大学的体外受精中心。70例至少3个CC治疗周期无效的不孕多囊卵巢综合征(PCOS)患者被随机分为两组。A组(n = 35)在月经周期第3 - 7天(CD3)服用5mg LTZ,B组(n = 35)在月经周期第5 - 9天(CD5)服用相同剂量。在月经周期第3天和LTZ治疗结束后3天(月经周期第10天或12天)进行激素水平检测和超声扫描。之后,如果超声扫描发现至少有一个卵泡≥18mm,则注射5000 - 10000IU人绒毛膜促性腺激素(hCG)。36 - 40小时后进行宫腔内人工授精(IUI)。比较两组的周期特征、排卵率和妊娠率。采用Fisher精确检验、t检验、逻辑回归和Mann - Whitney U检验进行统计学分析。
考虑患者特征,两组之间无显著差异。两组的排卵率(A组和B组分别为48.6%和32.4%)、子宫内膜厚度、成熟卵泡数量和卵泡期长度无显著差异。
LTZ是CC治疗失败的PCOS患者的有效治疗方法。月经周期第3天和第5天开始使用LTZ的两种不同方案在排卵率和妊娠率方面无显著差异(注册号:IRCT201307096467N3)。